Evidence map›Paper›PMID 40332249›Full record

ArticleInternational journal of molecular sciences2025

Combined Immune Checkpoint Blockade and Helixor

Anja Thronicke, Patricia Grabowski, Juliane Roos, Hannah Wüstefeld, Christian Grah, Sophia Johnson, Friedemann Schad

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mistletoe in Cancer Cell Biology: Recent Advances.Current issues in molecular biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anja ThronickeNetwork Oncology Registry, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.ORCID 0000-0002-6421-8290
Patricia GrabowskiInterdisciplinary Oncological Centre, Hospital Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
Juliane RoosInterdisciplinary Oncological Centre, Hospital Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
Hannah WüstefeldLung Cancer Center, Hospital Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
Christian GrahLung Cancer Center, Hospital Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
Sophia JohnsonNetwork Oncology Registry, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.
Friedemann SchadNetwork Oncology Registry, Research Institute Havelhöhe, Kladower Damm 221, 14089 Berlin, Germany.ORCID 0000-0002-6928-6209

Funding

Abnoba (Germany) n.n.Helixor Heilmittel (Germany) n.n.
6 · The paper itself

Abstract

Real-world data (RWD) play a crucial role in identifying key subgroups and assessing multimodal oncology therapies, including integrative and palliative care. Immune checkpoint blockade (ICB) has improved survival, and its combination with complementary therapies like

Indexed as

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsNeoplasmsPlant ExtractsAdultAgedAged, 80 and overFemaleHumansKaplan-Meier EstimateMaleMiddle AgedViscum albumImmune Checkpoint InhibitorsPlant ExtractsHelixor® Viscum album therapylung cancernon-small cell lung cancerPD-1 inhibitorPD-L1 inhibitorsurvival

Identifiers

PMID40332249
PMCPMC12027740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.